Combination therapy for bile duct and gallbladder cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two immunotherapy drugs, chemotherapy, and a targeted therapy to shrink bile duct or gallbladder cancers that are advanced but might be removable with surgery. The goal is to see if this approach can make surgery possible and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with intrahepatic cholangiocarcinoma or gallbladder cancer that is locally advanced or potentially removable with surgery.
- You have not had any prior treatment for this cancer.
- You are in generally good health, with a performance status of 0 or 1 (able to carry out daily activities).
- You have at least one measurable tumor that can be assessed by imaging.
- You do not have active autoimmune diseases, uncontrolled heart conditions, or severe infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two immunotherapy drugs (Tuvonralimab and Iparomlimab) given before surgery to shrink bile duct cancers that are borderline removable. The goal is to make the tumor easier to remove completely and improve outcomes.
This study tests whether adding another drug (lenvatinib or chemotherapy) to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for advanced bile duct or gallbladder cancer that has not been treated before. It aims to find a more effective first treatment option.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This study tests a combination of four drugs—two immunotherapy drugs (iparomlimab and toripalimab), a targeted therapy (bevacizumab), and chemotherapy—as a first-line treatment for advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to see if this combination can shrink tumors and help patients live longer.
This study tests a combination of freezing the tumor (cryoablation), an investigational immunotherapy (QL1706), and a targeted therapy pill (lenvatinib) for people with advanced bile duct cancer that has progressed after initial treatment. The goal is to see if this new combination can help control the cancer and improve outcomes.
This trial tests a combination of four drugs for people with advanced bile duct or gallbladder cancer that has spread. The drugs target HER2, a protein on some cancer cells, and may help shrink tumors or slow their growth.
Hear when a new BTC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.